Importer of Controlled Substances Application: Biopharmaceutical Research Company, 72895 [2024-20085]
Download as PDF
<![CDATA[
72895
Federal Register / Vol. 89, No. 173 / Friday, September 6, 2024 / Notices
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on July 30, 2024, Bright
Green Corporation, 1033 George Hanosh
Boulevard, Grants, New Mexico 87020,
applied to be registered as an importer
of the following basic class(es) of
controlled substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
Marihuana Extract ....................................................................................................................................................
Marihuana ................................................................................................................................................................
Tetrahydrocannabinols ............................................................................................................................................
The company plans to import tissue
culture that will be used to begin the
propagation of their bulk cannabis
manufacturing operation. No other
activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–20083 Filed 9–5–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1425]
Importer of Controlled Substances
Application: Biopharmaceutical
Research Company
Drug Enforcement
Administration, Justice.
AGENCY:
ACTION:
Notice of application.
Biopharmaceutical Research
Company has applied to be registered as
an importer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before October 7, 2024. Such
persons may also file a written request
for a hearing on the application on or
before October 7, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
SUMMARY:
In
accordance with 21 CFR 1301.34(a), this
is notice that on July 17, 2024,
Biopharmaceutical Research Company,
11045 Commercial Parkway, Castroville,
California 95012–3209, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
Drug code
lotter on DSK11XQN23PROD with NOTICES1
16:42 Sep 05, 2024
Jkt 262001
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–20085 Filed 9–5–24; 8:45 am]
BILLING CODE P
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
I
I
I
SUPPLEMENTARY INFORMATION:
Marihuana Extract ....................................................................................................................................................
Marihuana ................................................................................................................................................................
Tetrahydrocannabinols ............................................................................................................................................
VerDate Sep<11>2014
7350
7360
7370
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
Controlled substance
The company plans to import
Marihuana Extract (7350), Marihuana
(7360) and Tetrahydrocannabinols
(7370) as flowering plants and cannabis
derivatives to support analytical
chemistry analyses, research and the
manufacturing of dosage forms for preclinical and clinical trials. No other
activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
Schedule
Schedule
7350
7360
7370
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1429]
Importer of Controlled Substances
Application: Cambridge Isotope
Laboratories, Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
E:\FR\FM\06SEN1.SGM
06SEN1
I
I
I
]]>Agencies
[Federal Register Volume 89, Number 173 (Friday, September 6, 2024)]
[Notices]
[Page 72895]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-20085]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1425]
Importer of Controlled Substances Application: Biopharmaceutical
Research Company
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Biopharmaceutical Research Company has applied to be
registered as an importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for
further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants, therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
October 7, 2024. Such persons may also file a written request for a
hearing on the application on or before October 7, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on July 17, 2024, Biopharmaceutical Research Company,
11045 Commercial Parkway, Castroville, California 95012-3209, applied
to be registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Marihuana Extract....................... 7350 I
Marihuana............................... 7360 I
Tetrahydrocannabinols................... 7370 I
------------------------------------------------------------------------
The company plans to import Marihuana Extract (7350), Marihuana
(7360) and Tetrahydrocannabinols (7370) as flowering plants and
cannabis derivatives to support analytical chemistry analyses, research
and the manufacturing of dosage forms for pre-clinical and clinical
trials. No other activities for these drug codes are authorized for
this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-20085 Filed 9-5-24; 8:45 am]
BILLING CODE P
